Healthcare Business

Test tubes

Ionis Pharmaceuticals Drops on Dismissed Study

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) shares dropped severely after a less-than positive update on its IONIS-TTR Rx program. The company is currently evaluating IONIS-TTRRx in an ongoing Phase 3 study, ...
Read Full Story »
bigger fish

How Medivation Shareholders May Lose Big by Poison Pill in Hostile Takeover Fight With Sanofi

Sanofi S.A. (NYSE: SNY) wants Medivation Inc. (NASDAQ: MDVN) and it is going to extreme lengths to get it. Usually the term “hostile takeover” is an exaggeration, but in this case ...
Read Full Story »
Female patient on gurney

OvaScience Prices Secondary Offering

OvaScience Inc. (NASDAQ: OVAS) shares dropped early on Thursday following the pricing of its secondary offering. The company announced that it has priced its secondary offering of 7.15 million shares ...
Read Full Story »
100 dollar bills

Capital Infusions Are More Evidence of a Biotech Turnaround

The collapse of biotech giant Valeant Pharmaceuticals International Inc. (NYSE: VRX) has accelerated and possibly prolonged the biotech decline, infecting the entire sector. While negative news from the company and ...
Read Full Story »
mosquito

7 Companies in the Fight to Defeat the Zika Virus

In 2016, it is the Zika virus that has the public worried about the next pandemic. Past scares have been around Ebola, E. coli, SARS, mad cow, swine flu and ...
Read Full Story »
IPO

Selecta Biosciences Files for IPO

Selecta Biosciences has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were listed in the filing, but the offering ...
Read Full Story »
clinical trials

Why Sarepta’s PDUFA Delay Is a Good Thing

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares saw a handy gain on Wednesday following an analyst upgrade. Janney Montgomery Scott has a Neutral rating on Sarepta but increased its fair value estimate to ...
Read Full Story »
child with cancer

Cellectar Wins Big on New Patent

Cellectar Biosciences Inc. (NASDAQ: CLRB) watched its shares skyrocket on Wednesday morning following the announcement of a patent. The company announced that it has obtained a patent that covers CLR 1603, ...
Read Full Story »
Pfizer

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Needless to say, the health care sector, especially pharmaceuticals and biotech, have taken a rhetorical beating from politicians looking to force the blame for high drug prices on some of the ...
Read Full Story »
Female patient on gurney

5 Major Clinical Trial Results Coming Up

Pharmaceutical and biotech companies generally must endure the lengthy process that is getting their drug candidates to market through clinical trials. There is a fair amount to a great amount ...
Read Full Story »
Test tubes

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the May 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
white pills

Short Sellers Take Mixed Stance on Major Pharma

The short interest data have been released for the May 13 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
automatic inspection machine

PDL’s Next Acquisition Target Focus Is on Hypertension

PDL BioPharma Inc. (NASDAQ: PDLI) has now shown where its next revenue stream will be coming from. The company announced on Tuesday that it has committed to an equity investment ...
Read Full Story »
IPO

Selecta Biosciences Files for IPO: Targeting Gout

Selecta Biosciences has filed its paperwork with the Securities and Exchange Commission to conduct an initial public offering (IPO) ahead. The company applied to list its common stock on The ...
Read Full Story »
IPO

Nant Health Announces Potential Pricing for IPO

Nant Health registered an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company issued pricing details in this filing, expecting ...
Read Full Story »